Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Reaffirmed by Cantor Fitzgerald

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $21.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 169.23% from the company’s previous close.

Several other equities research analysts have also recently commented on ATNM. Maxim Group boosted their target price on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th. StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $25.72.

Actinium Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:ATNM opened at $7.80 on Tuesday. The stock has a market capitalization of $232.28 million, a P/E ratio of -4.56 and a beta of 0.01. Actinium Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $9.86.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter. On average, research analysts expect that Actinium Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several large investors have recently modified their holdings of ATNM. Sanders Morris Harris LLC acquired a new stake in shares of Actinium Pharmaceuticals during the first quarter worth $78,000. Creative Financial Designs Inc. ADV boosted its position in shares of Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares during the period. Finally, Brandywine Global Investment Management LLC purchased a new position in Actinium Pharmaceuticals in the 3rd quarter worth about $1,033,000. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.